35 related articles for article (PubMed ID: 36344048)
1. Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin.
Manna T; Thrower DA; Honnappa S; Steinmetz MO; Wilson L
J Biol Chem; 2009 Jun; 284(23):15640-9. PubMed ID: 19359244
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 exposure promotes PKG1-mediated phosphorylation and degradation of stathmin to increase epithelial barrier permeability.
Xie W; Chen M; Zhai Z; Li H; Song T; Zhu Y; Dong D; Zhou P; Duan L; Zhang Y; Li D; Liu X; Zhou J; Liu M
J Biol Chem; 2021; 296():100644. PubMed ID: 33839152
[TBL] [Abstract][Full Text] [Related]
3. Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma.
Davidson B; Skeie-Jensen T; Holth A; Hausladen S
Int J Gynecol Pathol; 2024 Jun; ():. PubMed ID: 38847524
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the expression of Stathmin and tumor immune cell infiltration in primary cervical carcinoma and its prognostic diagnostic value.
Yang H; Li H; Tang X; Zhang J; Zhang X
Heliyon; 2023 Dec; 9(12):e22585. PubMed ID: 38089980
[TBL] [Abstract][Full Text] [Related]
5. 2-Methoxyestradiol as an Antiproliferative Agent for Long-Term Estrogen-Deprived Breast Cancer Cells.
Hirao-Suzuki M; Kanameda K; Takiguchi M; Sugihara N; Takeda S
Curr Issues Mol Biol; 2023 Sep; 45(9):7336-7351. PubMed ID: 37754248
[TBL] [Abstract][Full Text] [Related]
6. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Eribulin on Stathmin Dynamics and Paclitaxel Sensitivity in Ovarian Cancer Cells.
Azumi M; Yoshie M; Takano W; Ishida A; Kusama K; Tamura K
Biol Pharm Bull; 2022; 45(11):1627-1635. PubMed ID: 36328498
[TBL] [Abstract][Full Text] [Related]
8. Stathmin dynamics modulate the activity of eribulin in breast cancer cells.
Yoshie M; Ishida A; Ohashi H; Nakachi N; Azumi M; Tamura K
Pharmacol Res Perspect; 2021 Aug; 9(4):e00786. PubMed ID: 34176226
[TBL] [Abstract][Full Text] [Related]
9. Class III
Yahiro K; Matsumoto Y; Fukushi JI; Kawaguchi KI; Endo M; Setsu N; IIda K; Fukushima S; Nakagawa M; Kimura A; Oda Y; Nakashima Y
Anal Cell Pathol (Amst); 2018; 2018():8987568. PubMed ID: 30034996
[TBL] [Abstract][Full Text] [Related]
10. KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway.
Zhao L; Zhang D; Shen Q; Jin M; Lin Z; Ma H; Huang S; Zhou P; Wu G; Zhang T
Oncogene; 2019 Feb; 38(7):935-949. PubMed ID: 30202098
[TBL] [Abstract][Full Text] [Related]
11. Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells.
Azumi M; Yoshie M; Nakachi N; Tsuru A; Kusama K; Tamura K
J Pharmacol Sci; 2022 Dec; 150(4):259-266. PubMed ID: 36344048
[TBL] [Abstract][Full Text] [Related]
12. Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition.
Lu Y; Liu C; Xu YF; Cheng H; Shi S; Wu CT; Yu XJ
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):386-94. PubMed ID: 25100123
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
